Iterum Therapeutics plc

Iterum Therapeutics plc operates as a pharmaceutical company focused on developing treatments for drug-resistant bacterial infections. The company's primary marketed product is ORLYNVAH, an oral penem antibiotic approved for treating uncomplicated urinary tract infections in adult women caused by specific gram-negative bacteria, where limited oral treatment alternatives exist. The company is also advancing sulopenem, a novel anti-infective compound available in both oral and intravenous formulations, across multiple indications including complicated urinary tract infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases.

The company operates with a minimal headcount of nine full-time employees and maintains operations across Ireland, Bermuda, and the United States. Iterum was incorporated in Ireland in 2015 and is listed on Nasdaq. The organization's revenue model centers on commercialization of its antibiotic portfolio, though specific segment breakdowns are not publicly detailed. The company's scale reflects a typical early-stage pharmaceutical developer focused on specialty infectious disease markets with limited commercial infrastructure.